株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

男性不妊治療の世界市場:2017年〜2021年

Global Male Infertility Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 321458
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
男性不妊治療の世界市場:2017年〜2021年 Global Male Infertility Market 2017-2021
出版日: 2017年03月10日 ページ情報: 英文 70 Pages
概要

世界における男性不妊治療市場は、2017年から2021年の間、5.68%のCAGR (複合年間成長率) で拡大することが予測されています。

当レポートでは、世界における男性不妊治療市場の現状分析と将来の見通し、市場の成長因子や課題、主要企業の分析などを提供しています。

第1章 エグゼクティブサマリー

第2章 当レポートの調査範囲

第3章 調査手法

第4章 イントロダクション

  • 主な市場洞察

第5章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第6章 根本的原因

第7章 技術

第8章 エンドユーザー別の市場

  • 市場概要
  • 不妊治療院
  • 病院および研究施設

第9章 地理区分

  • 市場概要
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域

第10章 意思決定の枠組み

第11章 市場成長因子

  • 主要顧客区分における成長因子の影響
  • 市場の課題
  • 主要顧客区分における課題の影響

第12章 市場動向

第13章 ベンダー情勢

  • 競合シナリオ

第14章 主要ベンダーの分析

  • ASKA Pharmaceutical
  • Halotech DNA
  • Merck Serono
  • Zydus Cadila Healthcare
  • その他の有力ベンダー

第15章 付録

  • 略語リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR12215

About Male Infertility

Male infertility is a widespread disorder, which refers to a male's inability to impregnate his fertile female partner. It occurs due to deficiencies in semen, poor sperm quality, lower hormonal support, and abnormal ejaculation.

Technavio's analysts forecast the global male infertility market to grow at a CAGR of 5.68% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global male infertility market for 2017-2021. To calculate the market size, the report considers the male infertility treatment, which includes products (drugs) and services.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Male Infertility Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • ASKA Pharmaceutical
  • Halotech DNA
  • Merck Serono
  • Zydus Cadila Healthcare

Other Prominent Vendors

  • AbbVie
  • Apricus Biosciences
  • Aytu BioScience
  • Bristol-Myers Squibb
  • CooperSurgical
  • Medical Electronic Systems
  • OvaScience
  • MedITEX
  • Xytex Cryo International

Market driver

  • Higher occurrence of diabetes among men
  • For a full, detailed list, view our report

Market challenge

  • High cost associated with treatment of male infertility
  • For a full, detailed list, view our report

Market trend

  • Monetary growth among consumers
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by under-lying cause

PART 07: Market segmentation by technique

PART 08: Market segmentation by end-user

  • Market overview
  • Fertility clinics
  • Hospitals and research institutes

PART 09: Geographical segmentation

  • Market overview
  • Male infertility market in Americas
  • Male infertility market in EMEA
  • Male infertility market in APAC

PART 10: Decision framework

PART 11: Market drivers

  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments

PART 12: Market trends

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key Vendor Analysis

  • ASKA Pharmaceutical
  • Halotech DNA
  • Merck Serono
  • Zydus Cadila Healthcare
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Causes of male infertility
  • Exhibit 02: Snapshot: Global male infertility market 2016-2021
  • Exhibit 03: Stages of infertility treatment
  • Exhibit 04: Impact of various factors on male infertility market
  • Exhibit 05: Types of sperm classification
  • Exhibit 06: Global male infertility market 2016-2021 ($ millions)
  • Exhibit 07: Key parameters for vendors entering the market
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Stages of diagnosis of male infertility
  • Exhibit 10: Facts related to oxidative stress
  • Exhibit 11: Global male infertility market by end-users (2016)
  • Exhibit 12: Risk factors in male infertility
  • Exhibit 13: Opportunity analysis of global male infertility market
  • Exhibit 14: Global male infertility market by geography 2016-2021
  • Exhibit 15: Snapshot: Global male infertility market by geography 2016-2021
  • Exhibit 16: Male infertility market in Americas 2016-2021 ($ millions)
  • Exhibit 17: Male infertility market in EMEA 2016-2021 ($ millions)
  • Exhibit 18: Male infertility market in APAC 2016-2021 ($ millions)
  • Exhibit 19: Estimated number of individuals with diabetes worldwide in 2015 and 2040 (millions)
  • Exhibit 20: Estimated cancer cases and deaths in US 2016 (in thousands)
  • Exhibit 21: Obesity prevalence in US 2015
  • Exhibit 22: Impact of drivers
  • Exhibit 23: Impact of challenges
  • Exhibit 24: Change in world's population by age 2010-2050
  • Exhibit 25: Key success strategies for vendors
  • Exhibit 26: ASKA Pharmaceutical profile
  • Exhibit 27: ASKA Pharmaceutical: Strength analysis
  • Exhibit 28: ASKA Pharmaceutical: Strategy assessment
  • Exhibit 29: ASKA Pharmaceutical: Opportunity assessment
  • Exhibit 30: Halotech DNA: Profile
  • Exhibit 31: Halotech DNA: Strength analysis
  • Exhibit 32: Halotech DNA: Strategy assessment
  • Exhibit 33: Halotech DNA: Opportunity assessment
  • Exhibit 34: Merck Serono: Profile
  • Exhibit 35: Merck Serono: Strength analysis
  • Exhibit 36: Merck Serono: Strategy assessment
  • Exhibit 37: Merck Serono: Opportunity assessment
  • Exhibit 38: Zydus Cadila Healthcare profile
  • Exhibit 39: ZydusCadila Healthcare: Strength analysis
  • Exhibit 40: Zydus Cadila Healthcare: Strategy assessment
  • Exhibit 41: ZydusCadila Healthcare: Opportunity assessment
Back to Top